VYNT - Vyant Bio, Inc. Stock Price, Fair Value and News

0.19USD Delayed

Market Summary

USD0.19

Delayed

VYNT Stock Price

View Fullscreen

VYNT RSI Chart

VYNT Valuation

Market Cap

1.2M

Price/Earnings (Trailing)

-0.05

Price/Sales (Trailing)

1.79

EV/EBITDA

0.58

Price/Free Cashflow

-0.08

VYNT Price/Sales (Trailing)

VYNT Profitability

Free Cashflow Yield

-1.2K%

VYNT Fundamentals

VYNT Revenue

VYNT Earnings

Breaking Down VYNT Revenue

Last 7 days

11.8%

Last 30 days

5.6%

Trailing 12 Months

-75.3%

How does VYNT drawdown profile look like?

VYNT Financial Health

VYNT Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	1.2M	1.1M	980.0K	666.0K
2021	2.2M	1.1M	1.1M	1.1M
2020	5.7M	4.1M	2.5M	867.0K
2019	5.3M	5.6M	7.1M	7.3M
2018	29.8M	24.5M	17.0M	11.2M
2017	27.9M	27.6M	28.8M	29.1M
2016	19.7M	22.6M	25.3M	27.0M
2015	13.1M	15.8M	16.6M	18.0M
2014	6.8M	6.5M	8.0M	10.2M
2013	4.7M	5.4M	5.8M	6.6M
2012	3.3M	3.7M	4.0M	4.3M
2011	0	0	0	3.0M
2010	0	0	0	2.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Vyant Bio, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 17, 2023	harris geoffrey e.	acquired	-	-	5,712	-
Jan 17, 2023	fletcher r john	acquired	-	-	4,368	-
Jan 17, 2023	horobin joanna	acquired	-	-	7,526	-
Jan 17, 2023	hansen paul r.	acquired	-	-	4,032	-
Nov 18, 2022	harris geoffrey e.	sold	-1,021	1.33479	-765	-
Oct 17, 2022	harris geoffrey e.	acquired	-	-	10,841	-
Oct 17, 2022	hansen paul r.	acquired	-	-	7,653	-
Oct 17, 2022	horobin joanna	acquired	-	-	14,285	-
Oct 17, 2022	fletcher r john	acquired	-	-	8,290	-
Jul 18, 2022	hansen paul r.	acquired	-	-	4,335	-

Which funds bought or sold VYNT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Aug 15, 2022	Frontier Wealth Management LLC	unchanged	-	-45,000	184,000	0.01%
Aug 12, 2022	Taylor Wealth Management Partners	reduced	-25.00	-11,000	9,000	-%

Are Funds Buying or Selling VYNT?

Are funds buying VYNT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VYNT

No. of Funds

Unveiling Vyant Bio, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	fod capital, llc	0.0%	0	SC 13G/A
Feb 14, 2022	fod capital, llc	5.09%	1,474,935	SC 13G
Feb 11, 2022	intracoastal capital, llc	0.0%	0	SC 13G/A
Feb 11, 2022	renaissance technologies llc	0.33%	96,342	SC 13G/A
Feb 09, 2022	lind global macro fund lp	2.3%	689,656	SC 13G/A
Feb 07, 2022	bigger capital fund l p	-	0	SC 13G/A

Peers (Alternatives to Vyant Bio, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Vyant Bio, Inc. News

Latest updates

Vyant Bio, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Revenue	-69.7%	46,000	152,000	165,000	303,000	360,000	256,000	329,000	203,000	265,000	335,000	1,446,000	1,667,500	1,889,000	2,069,000	1,525,000	1,822,000	1,689,000	535,000	1,281,000	7,667,000	7,523,000
Cost Of Revenue	-	-	-	-	-	-	-	-	-	987,000	912,000	640,000	814,000	972,000	993,000	734,000	1,002,000	-1,303,500	685,000	875,000	5,082,000	5,239,000
Gross Profit	-	-	-	-	-	-	-	-	-	324,000	656,000	806,000	612,000	917,000	1,076,000	791,000	820,000	-127,500	-150,000	406,000	2,585,000	2,284,000
Operating Expenses	-7.5%	3,544,000	3,833,000	4,501,000	4,700,000	4,423,000	3,532,000	4,260,000	4,639,000	2,059,000	3,105,000	1,186,000	2,140,000	1,121,000	4,718,000	1,501,000	1,967,000	-255,500	3,149,000	1,866,000	7,532,000	11,804,000
S&GA Expenses	22.7%	1,943,000	1,583,000	2,509,000	2,763,000	2,617,000	1,856,000	2,737,000	1,214,000	657,000	819,000	408,000	833,000	322,000	322,000	317,000	185,000	-401,500	320,000	386,000	1,591,000	1,553,000
R&D Expenses	-21.3%	1,568,000	1,993,000	1,688,000	1,551,000	1,359,000	1,211,000	910,000	820,000	767,500	867,000	593,000	1,000,000	-	-	7,000	454,000	-1,563,500	692,000	16,000	681,000	1,709,000
EBITDA Margin	-41.5%	-22.81	-16.12	-14.22	-12.08	-16.03	-16.22	-15.04	-6.38	-9.89	-2.32	-1.77	-1.14	-0.79	-	-	-	-	-	-	-	-
Interest Expenses	113.8%	62,000	29,000	11,000	-9,000	-5,000	-4,000	5,000	-368,000	-325,000	-210,000	36,000	1,000	109,000	200,000	514,000	615,000	114,000	82,000	2,000	239,000	1,331,000
Income Taxes	-	-	-	-	-	-	-	-	-	-8,000	2,000	-	6,000	-	-	-512,000	-	-	-	-	-	-1,109,000
Earnings Before Taxes	6.0%	-3,429,000	-3,647,000	-4,325,000	-4,406,000	-3,989,000	-3,274,000	-3,954,000	-7,358,000	-2,354,000	-2,990,000	-1,333,000	-1,973,000	91,000	-4,785,000	-967,000	-1,736,000	1,118,531	-3,437,000	733,000	-	-
EBT Margin	-42.1%	-23.73	-16.70	-14.75	-12.52	-16.18	-16.09	-14.71	-6.24	-9.98	-2.51	-1.96	-1.34	-1.01	-	-	-	-	-	-	-	-
Net Income	-23.0%	-4,259,000	-3,463,000	-5,805,000	-9,163,000	-24,846,000	-4,461,000	-4,186,000	-7,366,000	-2,354,000	-2,990,000	-1,333,000	-1,973,000	-293,000	1,975,000	-3,773,000	-4,617,000	-3,765,000	-8,519,000	-3,633,000	-4,456,000	-7,901,000
Net Income Margin	22.9%	-34.07	-44.16	-40.84	-34.18	-35.59	-17.44	-14.93	-6.24	-9.98	-2.66	-0.40	-0.71	-0.92	-	-	-	-	-	-	-	-
Free Cashflow	-32.0%	-3,301,000	-2,501,000	-4,494,000	-4,002,000	-3,017,000	-3,334,000	-6,566,000	-4,611,000	-1,520,000	-2,276,000	-541,000	-1,535,000	-2,530,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Assets	-34.0%	15,205	23,039	26,811	32,529	37,636	61,220	65,401	72,355	4,049	9,690	11,788	14,282	14,904	20,836	37,115	38,492	35,406	39,885	41,371	46,444	52,221
Current Assets	-5.1%	11,509	12,126	16,248	20,464	23,214	26,294	30,073	36,541	1,787	2,801	4,622	6,866	7,178	12,603	26,554	10,333	24,455	13,115	14,203	19,037	23,206
Cash Equivalents	6.5%	10,000	9,394	11,702	16,440	20,608	23,203	26,485	32,337	792	1,133	2,864	78.00	3,880	2,147	667	697	511	1,556	1,951	4,421	9,891
Inventory	-19.7%	53.00	66.00	437	497	475	480	407	409	415	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-9.6%	1,106	1,223	1,101	908	1,020	1,269	1,654	1,347	1,031	488	524	506	558	671	634	3,821	558	4,499	4,742	4,876	5,550
Goodwill	-	-	-	-	-	-	22,085	21,703	22,164	2,977	3,090	3,090	3,090	3,090	3,090	5,963	17,257	5,963	17,257	17,257	17,257	5,963
Liabilities	-42.4%	5,296	9,199	10,024	10,161	6,346	5,304	5,338	8,467	11,482	4,885	6,687	7,902	7,519	13,372	32,175	30,813	28,604	30,637	24,091	26,390	25,456
Current Liabilities	-45.2%	3,665	6,693	7,507	7,472	5,431	4,669	4,638	7,788	2,049	4,751	6,481	7,630	6,972	12,675	31,908	28,319	28,148	28,339	21,542	20,722	19,640
Long Term Debt	0%	57.00	57.00	57.00	57.00	57.00	57.00	57.00	57.00	6,839	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	0%	57.00	57.00	-	-	57.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-28.4%	9,909	13,840	16,787	22,368	31,290	55,916	60,063	63,888	36,440	4,805	5,101	6,380	28,257	7,464	4,940	7,679	6,802	9,248	17,280	20,054	26,765
Retained Earnings	-4.4%	-101,500	-97,244	-93,781	-87,976	-78,813	-53,967	-49,506	-45,320	-37,954	-168,656	-167,303	-165,603	-164,424	-164,131	-166,106	-162,333	-157,716	-153,951	-145,432	-141,799	-2,500
Additional Paid-In Capital	0.4%	111,443	111,009	110,627	110,411	110,176	109,864	109,567	109,205	1,514	173,517	172,431	171,853	171,783	171,696	171,021	170,022	164,458	163,092	162,575	161,801	161,527
Shares Outstanding	0.7%	5,922	5,883	5,883	5,882	5,798	4,096	3,231	637	519	495	494	492	421	-	-	-	-	-	-	-	-
Float	-	-	-	24,700	-	-	-	80,700	-	-	-	6,600	-	-	-	8,000	-	-	-	20,600	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Cashflow From Operations	-46.1%	-3,292	-2,254	-4,163	-3,972	-3,003	-3,320	-6,085	-4,585	-1,466	-2,309	-502	-1,535	-2,523	-1,277	-396	-4,464	-1,113	-3,338	-3,629	-4,472	-3,315
Share Based Compensation	5.2%	321	305	282	278	178	127	332	366	126	39.00	55.00	72.00	37.00	40.00	67.00	119	-37.00	189	268	274	500
Cashflow From Investing	1672.5%	3,947	-251	-373	-60.00	-73.00	49.00	-494	30,137	-54.00	-6.00	-11.00	28.00	6,068	3,078	-23.00	-32.00	364	-239	1,212	-253	-580
Cashflow From Financing	-104.1%	-8.00	197	-202	-136	481	-11.00	-10.00	6,730	357	4,260	417	1,298	-1,956	-201	351	5,111	-209	3,215	-146	-713	8,663

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VYNT Income Statement

2022-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 666	$ 1,148
Operating costs and expenses:
Research and development	6,772	4,273
Selling, general and administrative	8,798	8,424
Merger related costs		2,310
Total operating costs and expenses	16,578	16,854
Loss from operations	(15,912)	(15,706)
Other income (expense):
Change in fair value of warrant liability		214
Change in fair value of share-settlement obligation derivative		(250)
Loss on debt conversions		(2,518)
Other income	12	57
Interest expense, net	93	(372)
Total other income (expense)	105	(2,869)
Loss from continuing operations before income taxes	(15,807)	(18,575)
Income tax expense (benefit)
Loss from continuing operations	(15,807)	(18,575)
Discontinuing operations (net of ($21) and $0 tax (benefit) expense in 2022 and 2021, respectively)	(6,883)	(22,284)
Net loss	(22,690)	(40,859)
Cumulative translation adjustment	42	(74)
Comprehensive loss	$ (22,648)	$ (40,933)
Net loss per share attributed to common stock – basic and diluted:
Net loss per share from continuing operations	$ (2.69)	$ (4.11)
Net loss per share from discontinuing operations	(1.18)	(4.92)
Net loss per share	$ (3.87)	$ (9.03)
Weighted average shares outstanding:
Weighted average common shares outstanding – basic and diluted	5,868	4,525
Service [Member]
Revenue:
Total revenue	$ 99	$ 665
Operating costs and expenses:
Cost of goods sold – product	44	408
Product [Member]
Revenue:
Total revenue	567	483
Operating costs and expenses:
Cost of goods sold – product	$ 964	$ 1,439

VYNT Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 10,041	$ 20,608
Trade accounts and other receivables	323	434
Inventory	53	475
Prepaid expenses and other current assets	747	895
Assets of discontinuing operations – current	345	802
Total current assets	11,509	23,214
Non-current assets:
Fixed assets, net	1,106	1,020
Operating lease right-of-use assets, net	1,542	673
Long-term prepaid expenses and other assets	1,048	1,221
Assets of discontinuing operations – non-current		11,508
Total non-current assets	3,696	14,422
Total Assets	15,205	37,636
Current liabilities:
Accounts payable	655	740
Accrued expenses	1,154	764
Deferred revenue	72	74
Obligations under operating leases, current portion	313	174
Obligation under finance lease, current portion	252	157
Liabilities of discontinuing operations – current	1,219	3,522
Total current liabilities	3,665	5,431
Obligations under operating leases, less current portion	1,301	516
Obligations under finance leases, less current portion	273	293
Long-term debt	57	57
Liabilities of discontinuing operations – non-current		49
Total Liabilities	5,296	6,346
Commitments and Contingencies (Note 16)
Stockholders’ Equity
Preferred stock, authorized 9,764 shares $ 0.0001 par value, 0 shares issued and outstanding as of December 31, 2022 and 2021
Common stock, authorized 100,000 shares, $0.0001 par value, 5,922 and 5,798 shares issued and outstanding as of December 31, 2022 and 2021, respectively	1	1
Additional paid-in capital	111,443	110,176
Accumulated comprehensive loss	(32)	(74)
Accumulated deficit	(101,503)	(78,813)
Total Common Stockholders’ Equity	9,909	31,290
Total Liabilities and Stockholders’ Equity	$ 15,205	$ 37,636

About Vyant Bio, Inc.

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.

CEO	Mr. Andrew D.C. LaFrence CPA, CPA
WEBSITE	vyantbio.com
INDUSTRY	Biotechnology
EMPLOYEES	4

Vyant Bio, Inc. Frequently Asked Questions

What is the ticker symbol for Vyant Bio, Inc.? What does VYNT stand for in stocks?

VYNT is the stock ticker symbol of Vyant Bio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vyant Bio, Inc. (VYNT)?

As of Fri Dec 29 2023, market cap of Vyant Bio, Inc. is 1.19 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VYNT stock?

You can check VYNT's fair value in chart for subscribers.

What is the fair value of VYNT stock?

You can check VYNT's fair value in chart for subscribers. The fair value of Vyant Bio, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vyant Bio, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VYNT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vyant Bio, Inc. a good stock to buy?

The fair value guage provides a quick view whether VYNT is over valued or under valued. Whether Vyant Bio, Inc. is cheap or expensive depends on the assumptions which impact Vyant Bio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VYNT.

What is Vyant Bio, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 29 2023, VYNT's PE ratio (Price to Earnings) is -0.05 and Price to Sales (PS) ratio is 1.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VYNT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Vyant Bio, Inc.'s stock?

In the past 10 years, Vyant Bio, Inc. has provided -0.605 (multiply by 100 for percentage) rate of return.